Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) [Yahoo! Finance]
ImmunityBio, Inc. (IBRX)
Company Research
Source: Yahoo! Finance
ImmunityBio, Inc. (NASDAQ: IBRX is among the 12 Best Performing Stocks in February Piper Sandler Keeps an Overweight Rating on ImmunityBio, Inc. (IBRX) On March 4, 2026, Piper Sandler analyst Patrick Soon-Shiong increased ImmunityBio, Inc. (NASDAQ:IBRX)'s price objective to $12 from $7, maintaining an Overweight rating. The firm pointed out ANKTIVA's strong commercial momentum, reporting U.S. net revenues of approximately $113 million in 2025, noting a roughly 700% increase. Piper Sandler now forecasts ANKTIVA revenue of $195 million in 2026, showing that demand for the company's immunotherapy treatment remains strong. On February 26, 2026, ImmunityBio, Inc. (NASDAQ:IBRX) concluded enrollment in the Phase 2 QUILT 2.005 randomized study, which compared ANKTIVA + Bacillus Calmette-Guérin (BCG) to BCG alone in patients with BCG-naïve non-muscle invasive bladder cancer carcinoma in situ. The trial enrolled 366 patients and randomly assigned them to the two therapy groups ahead of s
Show less
Read more
Impact Snapshot
Event Time:
IBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBRX alerts
High impacting ImmunityBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBRX
News
- ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of ‘World Bank of NK Cells' [Yahoo! Finance]Yahoo! Finance
- Is It Too Late To Reassess ImmunityBio (IBRX) After Its 315% Year To Date Surge [Yahoo! Finance]Yahoo! Finance
- IBRX Stock: Anktiva's Approvals and What Comes Next [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer Donors [Yahoo! Finance]Yahoo! Finance
- ImmunityBio Achieves Milestone with Large-Scale NK Cell Production and Cryopreservation from Over 60 Healthy and Cancer DonorsBusiness Wire
IBRX
Earnings
- 5/12/25 - Miss
IBRX
Sec Filings
- 2/26/26 - Form 4
- 2/25/26 - Form SCHEDULE
- 2/24/26 - Form 4
- IBRX's page on the SEC website